Five products including two with orphan designation are likely to secure pan-EU approval within the next couple of months, having received the thumbs up last week from the European Medicines Agency’s key advisory committee, the CHMP.
As expected, the committee recommended against the approval of Puma Biotechnology’s potential new breast cancer treatment, Nerlynx (neratinib). No...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?